- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Eleanor Perfetto, PhD, MS, Discusses How HEOR Departments Use Comparative Effectiveness Research
Comparative effectiveness research (CER) collaborative tools can benefit pharmaceutical companies in a variety of ways.
Comparative effectiveness research (CER) collaborative tools can benefit pharmaceutical companies in a variety of ways. Eleanor Perfetto, PhD, MS, professor, pharmaceutical health services research, School of Pharmacy, University of Maryland, for instance, suggests that CER can be utilized in internal training programs as well as in making research studies translatable to managed care organizations and their leaders.
“For the most part, the responsibilities within the company are to get a drug approved, and that relies heavily on a randomized control trial design. Now that we have decision-makers who are out there looking at aspects beyond what the FDA would be looking for when a drug is being approved, they’re looking for some of the endpoints the FDA would consider secondary,” says Dr Perfetto.
She adds that the role of HEOR groups within pharmaceutical organizations will continue to grow and evolve.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
